Jp. Routy et al., INCREASE OF HEMOGLOBIN-A2 IN HUMAN IMMUNODEFICIENCY VIRUS-1-INFECTED PATIENTS TREATED WITH ZIDOVUDINE, American journal of hematology, 43(2), 1993, pp. 86-90
We observed increased hemoglobin A2 (HbA2) levels in an asymptomatic h
uman immunodeficiency virus-1 (HIV1) patient with no previous history
of beta-thalassemia. He was treated only with zidovudine (AZT). In an
attempt to understand this observation, a retrospective study was init
iated to determine whether mean HbA2 levels are higher in AZT-treated
patients than in subjects not receiving this drug and to assess if oth
er hematologic alterations are associated with elevated HbA2. One hund
red fifty-one HIV-positive cases were investigated; AZT was administer
ed to 81 of them. The mean value of HbA2 was 0.032 (SD +/- 0.005) for
the treated group vs. 0.027 (SD +/- 0.004) for the controls. This diff
erence was highly significant (P < 0.001). Twenty-four patients (31%)
in the treated group had elevated HbA2 levels vs. none in the controls
. Bone marrow toxicity seemed to be more significant in patients with
heightened HbA2 Values, and HbA2 levels did not increase with CDC clin
ical stage. We conclude that AZT may be linked to high HbA2 levels in
some patients.